This undated photo shows mockups of Boeing’s CST-100 Starliner and SpaceX’s Crew Dragon capsules with crew members, from left, Sunita Williams, Josh Cassada, Eric Boe, Nicole Mann, Christopher Ferguson, Douglas Hurley, Robert Behnken, Michael Hopkins and Victor Glover at the Johnson Space Center in Texas. (NASA via AP, file)

This undated photo shows mockups of Boeing’s CST-100 Starliner and SpaceX’s Crew Dragon capsules with crew members, from left, Sunita Williams, Josh Cassada, Eric Boe, Nicole Mann, Christopher Ferguson, Douglas Hurley, Robert Behnken, Michael Hopkins and Victor Glover at the Johnson Space Center in Texas. (NASA via AP, file)

More delays for Boeing’s new space capsule for astronauts

SpaceX flew its new Dragon capsule to the International Space Station last month.

You must sign in or register to continue reading content.

More in Herald Business Journal

Delta’s CEO expects Boeing will go ahead and build the ‘797’

The carrier’s CEO dangled the possibility of hundreds of jet sales if Boeing proceeds with the midrange jet.

Amazon vows to cut emissions to combat climate change

The announcement comes on the eve of tomorrow’s Global Climate Strike.

Apple’s iOS 13 features mean you may not need an iPhone 11

These five new features will perhaps convince you to stick with your current phone model.

FAA invites other nations to discuss work on grounded 737 Max

Some nations have begun saying they will perform independent assessments of the plane.

FAA chief meets Boeing officials, tries out 737 Max simulator

The FAA declined to say how the updated anti-stall software performed during Stephen Dickson’s session.

France floats tariffs on US goods amid Airbus-Boeing dispute

The World Trade Organization ruled in May that Europe illegally subsidized Airbus, hurting Boeing.

Business Highlights for Thursday, Sept. 19

Stunted consumer spending feared; Airbnb to go public; Walgreens to test drone deliveries.

A divided Fed reduces rates but may not cut again this year

The Fed’s move reduced its key short-term rate by an additional quarter-point to a range of 1.75% to 2%.

After bankruptcy filing, Purdue Pharma may not be off hook

The company’s owners expressed sympathy but not responsibility for the nation’s opioid crisis.

Most Read